Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies-Reference-Cited by-同舟云学术

Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies

Published:2021-11-16 Issue:28 Volume:40 Page:6235-6242
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

McCaw Zachary R.¹^ORCID,Tian Lu²^ORCID,Wei Jiawei³,Claggett Brian Lee⁴^ORCID,Bretz Frank⁵⁶^ORCID,Fitzmaurice Garrett⁷⁸,Wei Lee‐Jen⁸

Affiliation:

1. 1600 Amphitheatre Parkway Mountain View California

2. Department of Biomedical Data Science Stanford University Stanford California

3. Novartis Institutes for Biomedical Research Co. Shanghai China

4. Cardiovascular Division Brigham and Women's Hospital Boston Massachusetts

5. Novartis Pharma AG Basel Switzerland

6. Section for Medical Statistics Medical University of Vienna Vienna Austria

7. Laboratory for Psychiatric Biostatistics McLean Hospital Belmont Massachusetts

8. Department of Biostatistics Harvard T.H. Chan School of Public Health, Harvard University Boston Massachusetts

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.8971

Reference36 articles.

1. ICH Addendum: Statistical Principles for Clinical Trials.https://www.ich.org/page/efficacy‐guidelines#9‐2. Accessed August 18 2020

2. Estimands in clinical trials - broadening the perspective

3. Treatment Effects, Comparisons, and Randomization

4. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint;Statistical Methods in Medical Research;2024-08-06

2. Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials;2024-07-24

3. An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology;2024-04-01

4. Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML;Journal of Clinical Oncology;2023-09-20

5. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction;JAMA Cardiology;2023-06-01